A Phase 3, Double-blind, Parallel-group, Multicentre, Randomised-withdrawal, Long-term Maintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 with Attention-Deficit/Hyperactivity Disorder